New combo therapy shows promise for tough rectal cancer
Disease control
Recruiting now
This study tests whether adding an immunotherapy drug (PD-1 monoclonal antibody) and a targeted therapy (bevacizumab) to standard short-course radiation and chemotherapy can improve outcomes for people with a specific type of locally advanced rectal cancer (pMMR/MSS). About 86 pa…
Phase: PHASE2 • Sponsor: Dechang Diao • Aim: Disease control
Last updated May 06, 2026 16:01 UTC